Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
David d'AndreaPeter C BlackHomayoun ZargarColin P DinneyFrancesco SoriaMichael S CooksonJeffrey S MontgomeryWassim KassoufMarc A Dall'EraSrikala S SridharJohn S McGrathJonathan L WrightAndrew C ThorpeJeff M HolzbeierleinDiego M CarriónEttore Di TrapaniTrinity J BivalacquaScott NorthDaniel A BarocasYair LotanPetros GrivasAndrew J StephensonBas W van RhijnSiamak DaneshmandPhilippe E SpiessShahrokh F Shariatnull nullPublished in: The Journal of urology (2021)
Four cycles of NAC achieved better pathological response and survival compared to 3 cycles. These findings may aid clinicians in counseling patients and serve as a benchmark for prospective trials. Prospective validation of these findings and assessment of cumulative toxicity derived from an increased number of cycles are needed.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- muscle invasive bladder cancer
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- peritoneal dialysis
- transcription factor
- sentinel lymph node
- prognostic factors
- squamous cell carcinoma
- radiation therapy
- hepatitis c virus
- patient reported outcomes
- early stage